Compare Novartis AG (NVS) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Oracle Corporation — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Oracle Corporation trades at $148.01 (market cap $423.49B). The key difference: Oracle Corporation is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| NVS | ORCL | |
|---|---|---|
Market Cap | $298.18B | $423.49B |
Sector | Health | Technology |
52-Week High | $168.62 | $328.33 |
52-Week Low | $119.31 | $114.99 |
Enterprise Value | $339.50B | $552.74B |
Dividend Yield | 3.02% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Oracle (ORCL) trades at $145.45, down 1.02% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.11 beating expectations of $1.96, and fundamentals show robust revenue growth, reaching $57.4 billion in 2025, and high profitability with a net margin of 25.37%. Recent news highlights Oracle's AI infrastructure growth and a legal investigation into insider conduct.
Oracle's outlook is positive due to AI-driven demand and consistent earnings outperformance, supported by a consensus analyst price target of $253.63. Key risks include high valuation multiples, rising debt levels, and competitive pressures in cloud services. The stock offers growth potential but requires monitoring of execution risks and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
